Tìm theo
LJP 1082
Thuốc Gốc
Small Molecule
CTHH: C11H19N3O7S
PTK: 337.349
LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder. Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C11H19N3O7S
Phân tử khối
337.349
Monoisotopic mass
337.094370667
InChI
InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)
InChI Key
InChIKey=PIUSLWSYOYFRFR-UHFFFAOYSA-N
IUPAC Name
2-amino-4-({1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl}carbamoyl)butanoic acid
Traditional IUPAC Name
2-amino-4-{[1-(carboxymethylcarbamoyl)-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoic acid
SMILES
NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O
Độ hòa tan
5.27e+00 g/l
logP
-5.5
logS
-1.8
pKa (strongest acidic)
1.79
pKa (Strongest Basic)
9.31
PSA
179.05 Å2
Refractivity
75.2 m3·mol-1
Polarizability
32.24 Å3
Rotatable Bond Count
11
H Bond Acceptor Count
8
H Bond Donor Count
6
Physiological Charge
-1
Number of Rings
0
Bioavailability
0
Dược Lực Học : LJP 1082, a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.
Cơ Chế Tác Dụng : LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder. Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.
Chỉ Định : Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05446
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=1082
ChemSpider
http://www.chemspider.com/Chemical-Structure.1052.html
... loading
... loading